argenx SE
HealthcareNASDAQ:ARGX · NASDAQ Global Select
-$0.32 today
Vol 0.19M · Avg 0.32M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$6.3B of revenue converted into $2.3B of net income for the selected period. Gross margin is 79.4% and net margin is 36.5%, showing how much revenue survives after costs and taxes. EPS is $24.75, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2B +89.6% | $2.2B +78.6% | $1.2B +198.6% | $410.7M -17.4% | $497.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $450.7M +98.3% | $227.3M +92.9% | $117.8M +300.4% | $29.4M | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.7B +88.6% | $2.0B +77.1% | $1.1B +190.7% | $381.3M -23.3% | $497.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 89.1% -0.5pp | 89.6% -0.8pp | 90.4% -2.4pp | 92.8% -7.2pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.4B +38.7% | $983.4M +14.4% | $859.5M +29.6% | $663.4M +14.3% | $580.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.4B +28.9% | $1.1B +48.7% | $709.5M +51.0% | $469.9M +53.8% | $305.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.6B +33.4% | $2.0B +29.4% | $1.5B +39.2% | $1.1B +30.2% | $846.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $28.1M +60.3% | $17.5M -84.3% | $111.5M +6.8% | $104.3M +1678.5% | $5.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.3B +1146.3% | $105.2M +154.7% | -$192.3M +69.1% | -$622.8M -58.6% | -$392.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 31.6% +26.8pp | 4.8% +20.5pp | -15.7% +135.9pp | -151.6% -72.6pp | -79.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.1B +4970.3% | -$21.7M +94.9% | -$425.0M +41.0% | -$720.3M -106.6% | -$348.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 25.4% +26.4pp | -1.0% +33.7pp | -34.7% +140.7pp | -175.4% -105.2pp | -70.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $163.1M +17.8% | $138.5M +49.0% | $93.0M +275.7% | $24.7M +609.9% | $3.5M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.1M +84.0% | $2.2M +145.5% | $904.0K -58.8% | $2.2M +100.1% | $1.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $224.0M +109.7% | $106.8M -11.4% | $120.6M +1443.5% | -$9.0M +82.4% | -$51.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.3B +1401.1% | $85.2M +128.0% | -$304.5M +58.2% | -$729.3M -82.4% | -$399.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 30.8% +26.9pp | 3.9% +28.7pp | -24.8% +152.7pp | -177.6% -97.2pp | -80.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$13.4M +98.2% | -$747.9M -7819.7% | -$9.4M +52.1% | -$19.7M -331.4% | $8.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.3B +55.1% | $833.0M +382.3% | -$295.1M +58.4% | -$709.6M -74.1% | -$407.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 31.1% -6.9pp | 38.0% +62.1pp | -24.1% +148.7pp | -172.8% -90.8pp | -82.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $21 +51.9% | $14 +369.8% | -$5 +60.5% | -$13 -63.3% | -$8 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $20 +53.6% | $13 +347.7% | -$5 +60.5% | -$13 -63.3% | -$8 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $61.3M +2.4% | $59.9M +4.7% | $57.2M +5.1% | $54.4M +6.5% | $51.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $66.0M +1.3% | $65.2M +14.0% | $57.2M +5.1% | $54.4M +6.5% | $51.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.38B
Becton, Dickinson and Company
NYSE:BDX
$52.86B
Cardinal Health, Inc.
NYSE:CAH
$52.46B
Edwards Lifesciences Corporation
NYSE:EW
$48.78B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.09B
Haleon plc
NYSE:HLN
$40.31B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$37.92B
Agilent Technologies, Inc.
NYSE:A
$36.54B
Alcon Inc.
NYSE:ALC
$32.50B
Veeva Systems Inc.
NYSE:VEEV
$25.79B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ARGX generate?
argenx SE (ARGX) reported $4.15B of revenue in fiscal 2025.
Is ARGX profitable?
argenx SE (ARGX) reported $1.29B of net income, with a net margin of 31.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.